These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26223689)

  • 1. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
    Schuller Y; Hollak CE; Biegstraaten M
    Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
    Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
    Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
    Picavet E; Cassiman D; Simoens S
    J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
    Park T; Griggs SK; Suh DC
    BioDrugs; 2015 Aug; 29(4):259-74. PubMed ID: 26263903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.
    Grand TS; Ren S; Hall J; Åström DO; Regnier S; Thokala P
    Pharmacoeconomics; 2024 Jun; 42(6):619-631. PubMed ID: 38616217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
    Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
    Schlander M; Beck M
    Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.
    Moore DF; Ries M; Forget EL; Schiffmann R
    Pharmacoeconomics; 2007; 25(3):201-8. PubMed ID: 17335306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of economic evaluations of enzyme replacement therapy in Lysosomal storage diseases.
    Katsigianni EI; Petrou P
    Cost Eff Resour Alloc; 2022 Sep; 20(1):51. PubMed ID: 36123734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria.
    Coyle D; Cheung MC; Evans GA
    Med Decis Making; 2014 Nov; 34(8):1016-29. PubMed ID: 24990825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Schey C; Krabbe PF; Postma MJ; Connolly MP
    Orphanet J Rare Dis; 2017 Jan; 12(1):10. PubMed ID: 28095876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.